Can Trelegy Inhaler Be Used with Glaucoma?
Trelegy can be used in patients with glaucoma, but requires caution and close ophthalmologic monitoring, particularly in those with narrow-angle glaucoma where it should be avoided or used only with extreme vigilance.
Key Safety Considerations from FDA Labeling
The FDA label for Trelegy explicitly addresses glaucoma concerns 1. The anticholinergic component (umeclidinium) can increase intraocular pressure and worsen narrow-angle glaucoma. Trelegy should be used with caution in patients with narrow-angle glaucoma 1. The label warns that prescribers and patients must be alert for acute narrow-angle glaucoma symptoms including:
- Eye pain or discomfort
- Blurred vision
- Visual halos or colored images
- Red eyes from conjunctival congestion and corneal edema
Patients developing these symptoms require immediate ophthalmologic consultation 1.
Type of Glaucoma Matters Critically
Open-Angle Glaucoma (Lower Risk)
For patients with open-angle glaucoma, the evidence is reassuring:
- A randomized controlled trial found no clinically significant IOP increase in well-controlled open-angle glaucoma patients using inhaled fluticasone propionate for 6 weeks 2
- No participants exceeded their individualized target IOP 2
- A large UK database study of COPD patients found no association between fluticasone/salmeterol and incident glaucoma, with no dose-response relationship 3
Narrow-Angle Glaucoma (High Risk)
This is the critical contraindication scenario. The anticholinergic component can precipitate acute angle closure by causing pupillary dilation and angle narrowing 4. Ophthalmology guidelines specifically identify "ipratropium bromide and salbutamol-containing inhalers" and "drugs with anticholinergic activity" as potentially precipitating angle-closure attacks 4.
Risk Stratification Algorithm
Step 1: Determine glaucoma type
- If narrow-angle glaucoma or angle-closure suspect → Avoid Trelegy or use only with ophthalmology clearance
- If open-angle glaucoma → Proceed to Step 2
Step 2: Assess glaucoma control
- Well-controlled on current therapy with stable IOP → Can use Trelegy with monitoring
- Poorly controlled or unstable IOP → Ophthalmology consultation before initiating
Step 3: Consider family history
- Positive family history of glaucoma increases risk of IOP elevation with inhaled corticosteroids 5
- These patients need closer monitoring
Monitoring Requirements
For patients with open-angle glaucoma using Trelegy:
- Baseline ophthalmologic examination before initiating therapy 1
- Periodic IOP monitoring during long-term use 1
- Consider ophthalmology referral for patients developing ocular symptoms 1
- The FDA label specifically recommends considering ophthalmology referral for long-term users 6
Evidence on Inhaled Corticosteroid Risk
The corticosteroid component carries theoretical risk:
- High-dose inhaled corticosteroids (>1500 mcg/day) used for ≥3 months showed increased glaucoma risk (OR 1.44) 7
- However, patients with family history showed stronger association (OR 2.6), increasing to OR 6.3 with >4 puffs daily 5
- Patients without glaucoma family history showed no association 5
Common Pitfalls to Avoid
- Don't assume all glaucoma is the same - Narrow-angle is the dangerous scenario
- Don't forget the anticholinergic component - Umeclidinium poses greater acute risk than the corticosteroid in angle-closure disease
- Don't skip baseline eye examination - Essential for establishing type of glaucoma and baseline IOP
- Don't ignore family history - Significantly modifies risk with inhaled corticosteroids
Practical Management
For open-angle glaucoma: Trelegy is generally safe with appropriate monitoring. Document baseline IOP and ensure ophthalmology follow-up is established.
For narrow-angle glaucoma: Consider alternative COPD/asthma therapies without anticholinergics, or obtain ophthalmology clearance (possibly after laser peripheral iridotomy) before prescribing.
The real-world safety data from Japanese post-marketing surveillance showed low incidence of adverse events (8.4%) with no new safety concerns identified 8, though this wasn't specifically focused on glaucoma patients.